SALT LAKE CITY, May 26, 2020 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced its Australian subsidiary has completed over 50% of participant ...

Please provide your email address to receive an email when new articles are posted on . Nearly all patients in the open-label extension of VISIONARY-MS showed MRI evidence of neuronal repair and ...

COLUMBIA, SC — New research conducted by chemists at the University of South Carolina shows how nanoparticles of gold could help fight neurodegenerative diseases, such as Alzheimer’s Disease, ...

DENVER -- An oral suspension of clean-surfaced gold nanocrystals known as CNM-Au8 was safe and well-tolerated in patients with stable relapsing-remitting multiple sclerosis (MS) and chronic optic ...

Proprietary catalytic gold nanocrystals comprising Clene’s investigational drug CNM-Au8 ® develop a protein corona upon exposure to human blood plasma comprised of proteins that promote blood-brain ...

SALT LAKE CITY, Dec. 3, 2019 /PRNewswire/ -- Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the dosing of the first participant enrolled in the REPAIR-PD study ...

Results from phase two clinical trials at UT Southwestern Medical Center showed that a suspension of gold nanocrystals taken daily by patients with multiple sclerosis (MS) and Parkinson's disease (PD) ...

SALT LAKE CITY, March 01, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a ...